Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 9 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
REVENUES        
Neurometric information services $ 32,800 $ 25,000 $ 90,000 $ 81,400
Clinical services 158,000 172,800 499,100 456,000
Total revenues 190,800 197,800 589,100 537,400
OPERATING EXPENSES        
Cost of neurometric services revenues 35,500 37,800 110,700 110,300
Research 66,300 77,700 203,400 408,100
Product development 200,900 104,100 476,200 364,800
Sales and marketing 226,000 366,600 871,100 960,900
General and administrative 916,700 1,060,700 3,028,400 3,193,800
Total operating expenses 1,445,400 1,646,900 4,689,800 5,037,900
OPERATING LOSS (1,254,600) (1,449,100) (4,100,700) (4,500,500)
OTHER INCOME (EXPENSE):        
Interest expense, net (767,400) (2,117,100) (3,385,000) (6,073,200)
Financing fees 0 (59,300) (151,500) (348,500)
Offering costs (781,400) 0 (789,100) 0
Gain (Loss) on derivative liabilities 6,419,700 4,498,900 918,000 4,753,100
Total other income (expense) 4,870,900 2,322,500 (3,407,600) (1,668,600)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES 3,616,300 873,400 (7,508,300) (6,169,100)
Income taxes 1,100 0 2,000 1,300
NET INCOME (LOSS) $ 3,615,200 $ 873,400 $ (7,510,300) $ (6,170,400)
NET INCOME (LOSS) PER SHARE:        
Basic (Note 7) (in dollars per share) $ 1.93 $ 0.47 $ (4.01) $ (3.30)
Diluted (Note 7) (in dollars per share) $ 0.51 $ 0.22 $ (4.01) $ (3.30)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic (in shares) 1,874,175 1,870,813 1,873,902 1,868,731
Diluted (in shares) 7,100,407 3,949,420 1,873,902 1,868,731